NIH Renews Advisory Panel for Novel Biomedical Tech Insights
Published Date: 9/10/2025
Notice
Summary
The NIH is renewing the Novel and Exceptional Technology and Research Advisory Committee to keep advising on cool new biomedical tech. They’re holding a virtual meeting on September 29, 2025, to discuss public involvement in clinical research. This keeps important research moving forward with fresh ideas and public input, all without extra costs to taxpayers.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Virtual public meeting on Sept 29, 2025
You can view the NIH Novel and Exceptional Technology and Research Advisory Committee meeting virtually on September 29, 2025, from 1:00 p.m. to 3:00 p.m. ET via the NIH Office of Science Policy webcast link. The meeting is open to the public and meeting materials will be posted before the meeting. If you need special assistance or other reasonable accommodations to view the meeting, you should notify the contact person listed in the notice in advance.
Public comment submission and posting rules
Any interested person may file written comments to the contact person at least two business days prior to the meeting date; submissions must include name, address, telephone number, and when applicable business or professional affiliation. The notice asks that you not include personally identifiable, proprietary, classified, confidential, or sensitive information because NIH may post comments unredacted to the Office of Science Policy website.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2025-17379 — Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers
The National Cancer Institute is planning to give Lysin Therapeutics an exclusive license to use their special anti-mesothelin immunotoxins to treat cancers that have mesothelin. This means Lysin can develop and sell new cancer treatments, potentially helping patients with tough-to-treat tumors. The deal could speed up new medicines and impact cancer care soon, with business and health benefits on the horizon.
Next: 2025-17381 — Petition for Exemption; Summary of Petition Received; Hermeus Corporation
Hermeus Corporation asked the FAA for a special exemption from some aviation rules to help speed up their innovative aircraft projects. This change could affect how quickly new, super-fast planes get tested and flown, possibly shaking up the future of air travel. The FAA is sharing this info now to keep everyone in the loop and invite public feedback before making a decision.